170 related articles for article (PubMed ID: 27497648)
1. Simultaneous quantification of tenofovir, emtricitabine, rilpivirine, elvitegravir and dolutegravir in mouse biological matrices by LC-MS/MS and its application to a pharmacokinetic study.
Prathipati PK; Mandal S; Destache CJ
J Pharm Biomed Anal; 2016 Sep; 129():473-481. PubMed ID: 27497648
[TBL] [Abstract][Full Text] [Related]
2. UPLC-MS/MS method for the simultaneous quantification of three new antiretroviral drugs, dolutegravir, elvitegravir and rilpivirine, and other thirteen antiretroviral agents plus cobicistat and ritonavir boosters in human plasma.
Simiele M; Ariaudo A; De Nicolò A; Favata F; Ferrante M; Carcieri C; Bonora S; Di Perri G; De Avolio A
J Pharm Biomed Anal; 2017 May; 138():223-230. PubMed ID: 28219799
[TBL] [Abstract][Full Text] [Related]
3. Development and validation of an UPLC-MS/MS bioanalytical method for simultaneous quantification of the antiretroviral drugs dolutegravir, elvitegravir, raltegravir, nevirapine and etravirine in human plasma.
Bollen PDJ; de Graaff-Teulen MJA; Schalkwijk S; van Erp NP; Burger DM
J Chromatogr B Analyt Technol Biomed Life Sci; 2019 Jan; 1105():76-84. PubMed ID: 30572204
[TBL] [Abstract][Full Text] [Related]
4. Pharmacokinetics and Placental Transfer of Elvitegravir, Dolutegravir, and Other Antiretrovirals during Pregnancy.
Rimawi BH; Johnson E; Rajakumar A; Tao S; Jiang Y; Gillespie S; Schinazi RF; Mirochnick M; Badell ML; Chakraborty R
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28348149
[TBL] [Abstract][Full Text] [Related]
5. Impact of switching to TAF/FTC/RPV, TAF/FTC/EVG/cobi and ABC/3TC/DTG on cardiovascular risk and lipid profile in people living with HIV: a retrospective cohort study.
Giacomelli A; Conti F; Pezzati L; Oreni L; Ridolfo AL; Morena V; Bonazzetti C; Pagani G; Formenti T; Galli M; Rusconi S
BMC Infect Dis; 2021 Jun; 21(1):595. PubMed ID: 34157984
[TBL] [Abstract][Full Text] [Related]
6. A validated assay by liquid chromatography-tandem mass spectrometry for the simultaneous quantification of elvitegravir and rilpivirine in HIV positive patients.
Aouri M; Calmy A; Hirschel B; Telenti A; Buclin T; Cavassini M; Rauch A; Decosterd LA
J Mass Spectrom; 2013 May; 48(5):616-25. PubMed ID: 23674286
[TBL] [Abstract][Full Text] [Related]
7. 48-week efficacy and safety of dolutegravir relative to commonly used third agents in treatment-naive HIV-1-infected patients: a systematic review and network meta-analysis.
Patel DA; Snedecor SJ; Tang WY; Sudharshan L; Lim JW; Cuffe R; Pulgar S; Gilchrist KA; Camejo RR; Stephens J; Nichols G
PLoS One; 2014; 9(9):e105653. PubMed ID: 25188312
[TBL] [Abstract][Full Text] [Related]
8. A phase IV, open-label three-arm study investigating the impact of a combination of tenofovir disoproxil fumarate/emtricitabine with raltegravir or dolutegravir or elvitegravir/cobicistat on renal function in HIV-1 antiretroviral naïve patients.
Bracchi M; Pagani N; Dalla Pria A; Milinkovic A; Nwokolo N; Thomas L; Mandalia S; Boffito M; Moyle G
HIV Res Clin Pract; 2021 Oct; 22(5):128-139. PubMed ID: 34551678
[No Abstract] [Full Text] [Related]
9. Simultaneous determination and validation of emtricitabine, rilpivirine and tenofovir from biological samples using LC and CE methods.
Gumustas M; Caglayan MG; Onur F; Ozkan SA
Biomed Chromatogr; 2018 Apr; 32(4):. PubMed ID: 29216682
[TBL] [Abstract][Full Text] [Related]
10. Pharmacokinetics and tissue distribution of tenofovir, emtricitabine and dolutegravir in mice.
Labarthe L; Gelé T; Gouget H; Benzemrane MS; Le Calvez P; Legrand N; Lambotte O; Le Grand R; Bourgeois C; Barrail-Tran A
J Antimicrob Chemother; 2022 Mar; 77(4):1094-1101. PubMed ID: 35022753
[TBL] [Abstract][Full Text] [Related]
11. Simultaneous determination of intracellular concentrations of tenofovir, emtricitabine, and dolutegravir in human brain microvascular endothelial cells using liquid chromatography-tandem mass spectrometry (LC-MS/MS).
Patel SH; Ismaiel OA; Mylott WR; Yuan M; Hauser KF; McRae M
Anal Chim Acta; 2019 May; 1056():79-87. PubMed ID: 30797464
[TBL] [Abstract][Full Text] [Related]
12. Development, validation and clinical application of a method for the simultaneous quantification of lamivudine, emtricitabine and tenofovir in dried blood and dried breast milk spots using LC-MS/MS.
Waitt C; Diliiy Penchala S; Olagunju A; Amara A; Else L; Lamorde M; Khoo S
J Chromatogr B Analyt Technol Biomed Life Sci; 2017 Aug; 1060():300-307. PubMed ID: 28651173
[TBL] [Abstract][Full Text] [Related]
13. Spatial distribution of elvitegravir and tenofovir in rat brain tissue: Application of matrix-assisted laser desorption/ionization mass spectrometry imaging and liquid chromatography/tandem mass spectrometry.
Ntshangase S; Mdanda S; Naicker T; Kruger HG; Baijnath S; Govender T
Rapid Commun Mass Spectrom; 2019 Nov; 33(21):1643-1651. PubMed ID: 31240777
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of switching to dolutegravir plus emtricitabine/tenofovir disoproxil fumarate (TDF) or elvitegravir/cobicistat/emtricitabine/TDF in virologically suppressed HIV-infected patients in clinical practice: results from a multicentre, observational study.
Baldin G; Ciccullo A; Capetti A; Rusconi S; Sterrantino G; Cossu MV; Giacomelli A; Lagi F; Latini A; Bagella P; De Luca A; Di Giambenedetto S; Madeddu G
HIV Med; 2019 Feb; 20(2):164-168. PubMed ID: 30457197
[TBL] [Abstract][Full Text] [Related]
15. The development and application of a novel LC-MS/MS method for the measurement of Dolutegravir, Elvitegravir and Cobicistat in human plasma.
Penchala SD; Fawcett S; Else L; Egan D; Amara A; Elliot E; Challenger E; Back D; Boffito M; Khoo S
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Aug; 1027():174-80. PubMed ID: 27290668
[TBL] [Abstract][Full Text] [Related]
16. Decreased Absorption of Dolutegravir and Tenofovir Disoproxil Fumarate, But Not Emtricitabine, in an HIV-Infected Patient Following Oral and Jejunostomy-Tube Administration.
Brooks KM; Garrett KL; Kuriakose SS; George JM; Balba G; Bailey B; Anderson M; Lane HC; Maldarelli F; Pau AK
Pharmacotherapy; 2017 Aug; 37(8):e82-e89. PubMed ID: 28556353
[TBL] [Abstract][Full Text] [Related]
17. Pharmacokinetic profile of raltegravir, elvitegravir and dolutegravir in plasma and mucosal secretions in rhesus macaques.
Massud I; Martin A; Dinh C; Mitchell J; Jenkins L; Heneine W; Pau CP; García-Lerma JG
J Antimicrob Chemother; 2015 May; 70(5):1473-81. PubMed ID: 25630643
[TBL] [Abstract][Full Text] [Related]
18. Development and validation of a LC-MS/MS method for the quantification of tenofovir and emtricitabine in seminal plasma.
Illamola SM; Valade E; Hirt D; Dulioust E; Zheng Y; Wolf JP; Tréluyer JM
J Chromatogr B Analyt Technol Biomed Life Sci; 2016 Oct; 1033-1034():234-241. PubMed ID: 27571683
[TBL] [Abstract][Full Text] [Related]
19. A sensitive HPLC-MS/MS method for the determination of dolutegravir in human plasma.
Bennetto-Hood C; Tabolt G; Savina P; Acosta EP
J Chromatogr B Analyt Technol Biomed Life Sci; 2014 Jan; 945-946():225-32. PubMed ID: 24361860
[TBL] [Abstract][Full Text] [Related]
20. Development and validation of a multiplex UHPLC-MS/MS assay with stable isotopic internal standards for the monitoring of the plasma concentrations of the antiretroviral drugs bictegravir, cabotegravir, doravirine, and rilpivirine in people living with HIV.
Courlet P; Alves Saldanha S; Cavassini M; Marzolini C; Choong E; Csajka C; Günthard HF; André P; Buclin T; Desfontaine V; Decosterd LA
J Mass Spectrom; 2020 Jun; 55(6):e4506. PubMed ID: 32160389
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
